Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00103779 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT00103779 is a Phase 1 study that has completed, run by Seagen. The registered enrollment target is 50 participants.
The verdict
NCT00103779, a Phase 1 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is an open-label, multi-dose, Phase I, dose escalation study to define the safety profile and preliminary anti-tumor activity of SGN-40 in patients with refractory or recurrent non-Hodgkin B-cell lymphomas.
Interventions
- DRUG SGN-40 (anti-huCD40 mAb)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2004-12 |
| Est. Completion | 2007-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00103779
The ClinicalTrials.gov registry entry for NCT00103779 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SGN-40 (anti-huCD40 mAb) is the first listed.
NCT00103779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00103779 about?
NCT00103779 is a clinical study titled "A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma". This is an open-label, multi-dose, Phase I, dose escalation study to define the safety profile and preliminary anti-tumor activity of SGN-40 in patients with refractory or recurrent non-Hodgkin B-cell lymphomas.
What is the current status of trial NCT00103779?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2004-12. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00103779?
The interventions under investigation include: SGN-40 (anti-huCD40 mAb) (DRUG).
Who is sponsoring clinical trial NCT00103779?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.